Search

Your search keyword '"Viswanatha, David S."' showing total 463 results

Search Constraints

Start Over You searched for: Author "Viswanatha, David S." Remove constraint Author: "Viswanatha, David S."
463 results on '"Viswanatha, David S."'

Search Results

2. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events

5. A clinical laboratory–developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia

7. Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis

8. Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms

9. Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients

10. Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms

11. MYC dysregulation in the progression of multiple myeloma

13. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

15. The clinical and molecular spectrum ofETV6mutated myeloid neoplasms

17. Spectrum of clonal hematopoiesis in VEXAS syndrome

19. Contributors

21. Hematopoietic Stem Cell Transplant Outcome in STAG2-Mutated Myeloid Neoplasms

22. Correction to: Hybridization capture-based next-generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis

23. Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms

24. U2AF1 Mutant Clonal Hematopoiesis Is Infrequent, Context Dependent, and Commonly Co-Occurs with BCOR Mutations

25. IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort

26. Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies

27. Clonal Hematopoiesis in Vexas Syndrome

28. Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia with TP53 Mutations

29. Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms

33. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness

34. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia

35. The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.

36. Automation of hybridization and capture based next generation sequencing library preparation requires reduction of on-deck bead binding and heated wash temperatures

37. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas

40. Improved Characterization of Complex β-Globin Gene Cluster Structural Variants Using Long-Read Sequencing

41. Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN)

42. Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience

43. Expert Curation of Somatic FLT3 Variants By the Clingen Somatic Hematologic Cancer Taskforce (ClinGen HCT)

44. DDX41 Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic DDX41: Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort

45. Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90

47. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells

48. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations

49. Novel t(1;8)(p31.3;q21.3) NFIA-RUNX1T1 Translocation in an Infant Erythroblastic Sarcoma

50. Contributors

Catalog

Books, media, physical & digital resources